American Journal of Human Genetics Submission Guide: What to Prepare Before You Submit
American Journal of Human Genetics's submission process, first-decision timing, and the editorial checks that matter before peer review begins.
Readiness scan
Before you submit to American Journal of Human Genetics, pressure-test the manuscript.
Run the Free Readiness Scan to catch the issues most likely to stop the paper before peer review.
Key numbers before you submit to American Journal of Human Genetics
Acceptance rate, editorial speed, and cost context — the metrics that shape whether and how you submit.
What acceptance rate actually means here
- American Journal of Human Genetics accepts roughly ~20-30% of submissions — but desk rejection runs higher.
- Scope misfit and framing problems drive most early rejections, not weak methodology.
- Papers that reach peer review face a different bar: novelty, rigor, and fit with the journal's editorial identity.
What to check before you upload
- Scope fit — does your paper address the exact problem this journal publishes on?
- Desk decisions are fast; scope problems surface within days.
- Cover letter framing — editors use it to judge fit before reading the manuscript.
How to approach American Journal of Human Genetics
Use the submission guide like a working checklist. The goal is to make fit, package completeness, and cover-letter framing obvious before you open the portal.
Stage | What to check |
|---|---|
1. Scope | Manuscript preparation |
2. Package | Submission via Editorial Manager |
3. Cover letter | Editorial assessment |
4. Final check | Peer review |
Quick answer: This American Journal of Human Genetics submission guide starts with the key editorial reality. AJHG is the ASHG flagship human-genetics journal published by Cell Press with Kiran Musunuru as Editor-in-Chief, accepting submissions at . The first gate is not whether the paper has genetic data. It is whether the manuscript behaves like broad, field-useful human genetics from page one.
Run an American Journal Of Human Genetics pre-submission readiness check before clicking submit, or work through this guide manually.
From our manuscript review practice
The most common AJHG mistake is assuming that any genetics paper automatically belongs in the human-genetics flagship. At this journal, the audience and field consequence have to be obvious early.
What evidence basis and source limits shape this AJHG guide?
This page exists to help authors decide whether AJHG is the right target before upload. It should help before you submit by separating human-genetics fit from generic genetics data quality. It was reviewed against ASHG's AJHG page, AJHG author-side materials, official author guidance, the public submission-system route, public journal-profile data, and Manusights pre-submission review patterns from human-genetics manuscripts.
Official and generic pages for American Journal of Human Genetics submission guide queries mostly point authors to ASHG pages, Cell Press author information, submission-system links, and generic journal facts. Those pages are necessary, but they do not answer the decision authors actually face: whether the manuscript reads like a broad human-genetics contribution rather than a narrow disease, methods, model-organism, or clinical implementation paper.
Use this guide for the editor-facing fit layer. ASHG describes AJHG as its flagship scientific journal, states that manuscripts should be accessible to professionals from diverse backgrounds in human genetics, and says all submissions are initially evaluated in depth by editors. Official guidance cannot tell whether a specific title, abstract, variant analysis, model-organism bridge, figure sequence, and cover letter make that field-level consequence visible enough for triage. What editors actually want is not more genetics vocabulary, but a manuscript whose audience, evidence, and interpretation all point to broad human genetics.
Of the 100 AJHG-style manuscripts and published-paper packages our team reviewed when this guide was built, the stronger drafts made the broad human-genetics consequence, functional or interpretive follow-through, model-organism bridge, population-genetics context, ethics and consent statements, data availability, cover letter, and HGG Advances routing visible before the editor had to infer field ownership. Manusights internal analysis identifies five recurring failure patterns for AJHG-bound submissions: association results without enough interpretation, model-organism evidence with a soft human-genetics bridge, disease framing too narrow for the flagship community, methods papers without a practical genetics use case, and cover letters that argue prestige rather than field ownership.
Evidence boundary: we did not test the private Editorial Manager workflow in this pass. This guide is based on public official-source guidance, public journal facts, and anonymized Manusights submission analysis, so it should be used as a pre-upload editorial-readiness guide rather than a substitute for the journal's live author instructions.
This guide tells you what American Journal of Human Genetics editors look for before reviewer assignment, and Manusights checks whether YOUR paper passes the broad-human-genetics, association-interpretation, model-organism bridge, ethics/consent, data-availability, cover-letter, display-budget, and Cell Press/ASHG routing checks that official AJHG guidance cannot evaluate from a generic checklist. Paid Manusights reviews are covered by a 60-day money-back guarantee, and we never train on submitted manuscripts.
If you want the quick pre-upload call, run an American Journal of Human Genetics submission readiness check before opening the AJHG submission system.
What are the American Journal of Human Genetics key submission facts?
Requirement | Details |
|---|---|
2024 JIF | 8.1 |
Publisher | Cell Press for the American Society of Human Genetics (ASHG) |
Editor-in-Chief | Kiran Musunuru, MD, PhD, MPH, ML, MRA |
Journal posture | Flagship human-genetics journal |
Core article classes | Articles, Reports, Commentaries, Letters |
Article length cap | Articles no more than 60,000 characters (~9,000 words including refs); Reports no more than 25,000 characters (~3,750 words) |
Display items cap | Up to 7 figures + tables in Articles; up to 4 in Reports |
Abstract limit | 200 words |
Scope nuance | Model-organism studies are welcome only when directly relevant to human genetics |
Sex / gender reporting | Required per 2023 NASEM report on population descriptors |
Editorial decision target | Editors make every effort to reach decisions within 4 weeks |
ASHG member charges | Corresponding authors who are ASHG members do not pay page charges or color figure charges |
Submission portal | (Cell Press Editorial Manager) |
Portfolio reality | Papers not accepted at AJHG may be offered transfer to HGG Advances |
How does AJHG editorial triage work?
AJHG's editorial workflow runs on a fast cadence relative to flagship Nature / Cell / Science venues. The day/week timeline below reflects published targets at . Editors screen for human-genetics field consequence, accessible framing, and model-organism relevance in the first read.
Day 1-3: Receipt and tech-check
Editorial Manager confirms file integrity, ORCID for corresponding author, COI / funding declarations, sex / gender reporting per 2023 NASEM guidance, and the cover-letter field-fit case. Technical-return rather than desk-reject is standard for missing artifacts.
Day 3-7: Editor-in-Chief assignment
Kiran Musunuru, Editor-in-Chief, or a handling editor takes the paper. The scope read decides whether the contribution is broad-flagship human-genetics work or better suited to HGG Advances, Genetics in Medicine, or a more specialty venue.
Week 2-4: First decision
The journal targets first decisions within 4 weeks of submission. The decision is desk-reject (with optional offered transfer to HGG Advances), R&R, send-to-review, or accept-without-major-changes. Desk-reject decisions in this window cite either field consequence (too narrow), model-organism relevance (too indirect), or owner journal mismatch.
Week 4-12: External peer review (if sent)
At least two reviewers who have agreed in advance to assess the paper rapidly. Reviewer-report turnaround is faster than typical Cell Press tracks because reviewers pre-commit to timelines.
Week 12-16: Revision cycle
If revisions are requested, authors get 4 weeks. Only one revised version is considered. Accepted papers publish within 2 months of acceptance.
What is AJHG actually screening for?
AJHG is broad within human genetics, but still selective about what counts as broad enough. Editors are usually asking:
- is this genuinely a human-genetics or human-genomics paper rather than a general biology paper with some genetic data
- does the manuscript matter to a broad field readership rather than only to one methods niche or one disease micro-community
- if model organisms are involved, is the link to human genetics direct and load-bearing
- does the paper move beyond reporting associations, variants, or datasets into something the field can use conceptually
That is why technically strong papers still miss here. The work can be real and the field ownership can still be wrong.
What checklist should you use before you submit?
Pressure-test these questions before upload:
- the title and abstract say what changed for human genetics, not only what dataset was analyzed
- the paper is intelligible to readers outside your exact specialty inside genetics
- a model-organism result clearly resolves a human-genetics question rather than only suggesting one
- the manuscript explains why the finding matters to the wider community of geneticists, not just to one disease area
- the cover letter can explain why AJHG is the right owner rather than Nature Genetics, Genome Research, Genetics in Medicine, or HGG Advances
If those answers are weak, the paper is usually early for this target.
Use this checklist as a final decision artifact, not just an administrative task: title, abstract, first figure, model-organism bridge, data availability, ethics and consent language, and cover letter should all answer the same field-ownership question.
Readiness check
Run the scan while American Journal of Human Genetics's requirements are in front of you.
See how this manuscript scores against American Journal of Human Genetics's requirements before you submit.
What do the official AJHG materials make explicit?
The public ASHG pages are useful because they reveal the journal's real posture without overexplaining it.
Official signal | Why it matters |
|---|---|
AJHG is described as ASHG's flagship scientific journal | Community-facing field ownership matters here |
The journal welcomes articles, reports, and commentaries across human genetics and genomics | Match the contribution class honestly before submission |
Model-organism studies are in scope only when directly relevant to human genetics | Indirect relevance is usually not enough |
Manuscripts should be accessible to professionals from diverse backgrounds in human genetics | Narrow field jargon and local framing hurt first-read clarity |
The journal may transfer declined papers to HGG Advances | Editors are implicitly sorting for flagship-level consequence versus solid field work |
The practical implication is straightforward: AJHG wants papers that the broader human-genetics community can use and recognize quickly.
What package works best here?
1. A manuscript written for human geneticists, not just for your local specialty
AJHG papers usually signal early why the result changes disease genetics, population genetics, statistical genetics, or human-genomics interpretation. If the introduction reads like a methods subfield paper or a disease-specific paper, editorial momentum weakens.
2. An evidence package that goes beyond raw association or raw cataloging
This is one of the journal's most common pressure points. Association studies, variant-discovery studies, and population analyses can all fit, but they need interpretation, follow-through, or a clear field consequence. A paper that mainly says "we found these loci" or "we identified these variants" often feels incomplete at this level.
3. Honest handling of model-organism relevance
AJHG explicitly leaves room for model-organism work, but only when the relevance to human genetics is direct. That means a yeast, zebrafish, fly, or mouse result cannot be left hanging as a suggestive analogy. The human-genetics consequence needs to be obvious.
4. A cover letter that makes the field-level case
At this level, the cover letter should not be a generic novelty statement. It should explain what changed for the human-genetics field, who in the field should care, and why this is flagship-community work rather than only sound specialty work.
What artifacts does the AJHG submission package require?
Editors screen AJHG uploads against the following artifacts on first-pass tech-check. Missing any of the first five triggers a technical-return rather than a substantive desk reject.
The required artifacts are the cover letter (with field-fit case and any prior-rejection / portfolio context), the manuscript file in Cell Press standard format, the structured abstract (no more than 200 words), the ORCID identifier for the corresponding author (encouraged for all co-authors), the conflicts-of-interest declaration, the funding-source statement, the author contributions statement, the data availability statement (Cell Press strongly prefers public repositories: dbGaP, EGA, GEO, GenBank, ClinVar), the ethics / IRB approval and consent statement (where human-subjects work is involved), the sex / gender reporting per 2023 NASEM guidance, and 3-5 suggested reviewers. Supplementary materials (extended methods, additional figures, datasets) accompany the main manuscript.
What common mistakes hurt AJHG submissions?
1. Association without enough interpretation
AJHG is full of papers that become working references for the field. That means association-heavy studies usually need stronger functional, mechanistic, translational, or inferential follow-through than authors initially think.
2. Model-organism work with soft human relevance
This is a recurring fit mistake. The biology may be clean, but if the bridge to human genetics is mostly rhetorical, the paper looks better suited elsewhere.
3. A paper that is too clinically narrow or too methods narrow
Some manuscripts belong in Genetics in Medicine or the American Journal of Medical Genetics because the center of gravity is clinical implementation. Others belong in a methods or computational venue because the main audience is technical. AJHG sits in a middle lane where broad human-genetics consequence is the real standard.
Before upload, an AJHG readiness check can tell you whether the paper is underdeveloped scientifically or simply pointed at the wrong journal owner.
What should the AJHG cover letter do?
The cover letter should answer a short list of questions quickly:
- what the paper changes for the human-genetics field
- why the result matters beyond one local disease or methods niche
- how the study earns a flagship human-genetics readership
- whether there are related manuscripts, transfers, or portfolio context the editor should know
The strongest AJHG letters do not sound grandiose. They sound field-aware. They explain why a broad set of human geneticists would care now.
In our pre-submission review work with manuscripts targeting American Journal of Human Genetics
In our pre-submission review work with human-genetics manuscripts targeting American Journal of Human Genetics, three recurring decision risks matter most across submissions that AJHG editors filter out at the desk-screen stage. (Per Cell Press / ASHG published guidelines, AJHG is ASHG's flagship journal for human genetics and genomics including studies of model organisms directly relevant to human genetics; covers Mendelian disorders, complex traits, epidemiological studies, population genetics, novel tools / technologies for genetic analysis, and advances in medical applications; all submissions are evaluated in depth by editors with desk-rejection decisions in 3-5 days; full-review decisions targeted within 4 weeks. The editorial bar is "important findings across human genetics and genomics" with strong-human-genetics-consequence rather than technically-competent data generation alone.) Use the three checks below before you open editorialmanager.com/ajhg upload slot.
Genetically-interesting but not broadly human-genetics important where the contribution's audience is narrower than the AJHG community standard requires
In our review work with AJHG-targeted manuscripts, we consistently see authors submit work that is technically competent and locally interesting (single-family pedigree study of an ultra-rare phenotype without broader genetic-mechanism relevance, narrow disease-cohort association study without cross-disease implications, model-organism functional genomics study where the human-genetics bridge is asserted but not demonstrated, methods paper validating a technique on existing data without genetics use case, ancestry-specific genetic-architecture paper without broader population-genetics framing) but whose actual audience is smaller than the broad human-genetics community AJHG serves. AJHG editors apply the documented broad-human-genetics-importance test at desk: a reader from a different human-genetics subfield (Mendelian disease genetics vs complex-trait GWAS vs functional genomics vs population genetics vs clinical genetics vs computational methods vs pharmacogenomics vs cancer genetics vs developmental genetics) must be able to articulate why the result matters for their work. Specific patterns AJHG editors flag at desk: title and abstract name one specific disease / phenotype / population as the primary frame without broader implications; introduction cites primarily within-subfield literature without engaging cross-subfield debates; results presented as "we identified X variant in disease Y" without broader genetic-mechanism / pathway / target-pharmacology implications; methods paper demonstrating technical capability on simulated or single-dataset application without genetic-use-case demonstration; ancestry-specific analysis without comparative cross-ancestry framing or methodological-equity contribution. Manuscripts where the broad-importance case is weak get desk-rejected within 3-5 days with redirect to: Human Genetics and Genomics Advances (HGG Advances, the Cell Press sister for solid human-genetics work that does not clear AJHG's flagship bar); Genetics in Medicine (American College of Medical Genetics, for clinical-implementation focus); Human Molecular Genetics (Oxford UP for broader human-molecular-genetics); European Journal of Human Genetics (ESHG for broader scope); Genome Research (CSHL for genomics methods and discovery); PLOS Genetics (broader open-access genetics); BMC Genomics (broader genomics); Genetics (GSA for broader transmission genetics); GWAS Catalog / Annals of Human Genetics for ancestry-specific work; specialty disease venues (Brain for neurogenetics, Blood for hematologic, Diabetes for diabetes-genetics, Journal of the American College of Cardiology for cardiovascular genetics, Cancer Cell / Nature Cancer for cancer genetics, Pediatric Research for pediatric genetics, JAMA Neurology for clinical neurogenetics). The fix is to identify the broad human-genetics implication the work has, name it explicitly in the abstract, demonstrate cross-subfield relevance with engagement of multiple human-genetics communities in the introduction, and either invest in the broad-relevance argument or route honestly to HGG Advances (the most natural alternative for solid but not flagship-level human-genetics).
Check whether your AJHG manuscript proves broad human-genetics consequence →
Association / burden / variant manuscript without sufficient interpretation or consequence case (functional validation, mechanism, clinical translation)
In our pre-submission review work, we observe that AJHG manuscripts frequently report variant-discovery findings (rare-variant burden test result, GWAS locus, ExWAS / PheWAS finding, copy-number-variant association, structural-variant discovery, mosaic mutation finding) with strong statistical evidence but insufficient downstream interpretation or consequence case. AJHG handling editors specifically check whether: the discovery is followed by functional validation (cell-based or organoid experiment demonstrating the variant's molecular consequence; named expression / splicing / protein-stability / localization / function readout with quantitative analysis; rescue experiment with wild-type allele); mechanistic insight goes beyond identification (named pathway / network / regulatory mechanism with computational / experimental support; epistatic or environmental-interaction analysis where relevant; gene-set enrichment with biological interpretation); clinical-relevance discussion is concrete (named clinical actionability: drug target / therapeutic biomarker / diagnostic application / risk-prediction utility; ACMG variant-pathogenicity classification implications; named clinical-genetics consortia or registries the finding informs); reproducibility evidence is strong (named replication cohort with population-genetics matching, named control with appropriate ancestry-correction, biobank-scale evidence where available); broader population-genetics context is addressed (effect size compared to common-variant burden, ancestry-specific frequencies and effects, evolutionary-constraint analysis via gnomAD or similar). Manuscripts that report discovery without one of these elements face desk rejection or major revision with redirect to: HGG Advances (where the discovery-only paper may fit), Genetics in Medicine (clinical-translation focus), American Journal of Medical Genetics (clinical case-report and broader clinical), Journal of Medical Genetics (BMJ broader medical genetics), Clinical Genetics, Molecular Genetics & Genomic Medicine, Genome Medicine (clinical-genomics focus). The fix is to design the study with functional validation alongside discovery (not add validation after discovery), include mechanistic insight in the main paper (computational or experimental), make the clinical relevance concrete with named applications, and ensure the discovery is followed by interpretive value the field can act on.
Check whether your AJHG association evidence has enough interpretation →
Venue-misrouting between AJHG (ASHG flagship), Nature Genetics (broader genetics flagship), Genome Research, Genetics in Medicine, HGG Advances, and human-genetics sister journals
In our pre-submission review work with AJHG-targeted manuscripts, the third pattern we see consistently is misrouting within the human-genetics journal landscape. AJHG handling editors specifically check whether the contribution fits AJHG (ASHG flagship for broad human-genetics importance with Cell Press editorial standards; Article + Report + Commentary article types) or another venue: Nature Genetics (Nature-portfolio flagship for genetics across organisms with stronger broad-significance bar and broader audience including model-organism genetics; higher IF, lower acceptance, longer review); Genome Research (CSHL flagship for genomics methods and discovery, more technically-focused with stronger genomics-methods emphasis); Genome Biology (BMC OA for broader genomics including methods); Nature Medicine / Nature Communications (broader Nature-portfolio for clinical-genomics applications); Genetics in Medicine (ACMG flagship for clinical-genetics implementation with stronger clinical and policy framing); Human Genetics and Genomics Advances (HGG Advances, Cell Press OA sister for solid human-genetics work that does not clear AJHG flagship bar; broader scope including methodology papers); Human Molecular Genetics (Oxford UP for broader human-molecular-genetics); European Journal of Human Genetics (ESHG for European-anchored broader); Genetics (GSA for broader transmission genetics including model-organism); PLOS Genetics (broader OA genetics); Cell (Cell Press flagship when contribution is broader cell-biology with genetics component); Cell Genomics (Cell Press genomics specialty); Nature Reviews Genetics / Annual Review of Genomics and Human Genetics (review-shaped); American Journal of Medical Genetics Parts A / B / C (broader clinical / neuropsychiatric / case-report); specialty venues (Brain, Blood, JACC, Diabetes, Cancer Cell, Pediatric Research for disease-specific). Manuscripts misrouted face desk redirects within 3-5 days. The fix is to read 3-5 recent papers from AJHG / Nature Genetics / Genome Research / Genetics in Medicine / HGG Advances before choosing, identify the contribution's center of gravity (broad human-genetics importance with discovery + interpretation = AJHG; broader genetics with model-organism component = Nature Genetics; genomics methods or discovery = Genome Research; clinical implementation = Genetics in Medicine; solid but not flagship-level human-genetics = HGG Advances), and write the cover letter to justify AJHG specifically over the sibling alternatives.
Check whether your AJHG manuscript passes the Sullivan-pass substance screen →
AJHG versus peer human-genetics journals
This peer-comparison table compares AJHG with the four journals most often considered alongside it. Numbers are JCR 2024 IFs, published acceptance ranges where available, and the typical evidence threshold each title applies. Authors weighing AJHG against Cell Press flagships, Nature Portfolio, Science, NEJM, PNAS, BMJ, or Lancet venues should expect different rigor and scope expectations at each.
Journal | Impact Factor (2024) | Acceptance rate | Decision turnaround | Best fit | Think twice if |
|---|---|---|---|---|---|
AJHG | 8.1 | ~14% | 4 weeks (target) | Broad human-genetics community consequence | Mainly narrow clinical or technical-methods reporting |
Nature Genetics | 25-30 | ~5-8% | 8-12 weeks | Cross-biology consequence + flagship-level discovery | Strongest fit is field-facing human-genetics breadth |
Genome Research | 6-7 | ~15-20% | 6-10 weeks | Genomics dataset + analysis is the centerpiece | Real value is human-genetics interpretation |
Genetics in Medicine | 6-7 | ~20% | 6-12 weeks | Clinical implementation + medically applied genetics | Contribution is not clinical practice or service delivery |
HGG Advances | 4-5 | ~30% | 4-6 weeks | Solid genetics + genomics without flagship-lane breadth | Manuscript is genuinely built for AJHG's flagship stage |
Source: Cell Press / Nature Portfolio / ASHG journal pages, JCR 2024, accessed May 2026.
The honest target usually depends on who should remember the paper a year from now.
Submit If
- the manuscript changes how a broad human-genetics readership would think about the problem
- the paper moves beyond simple association or cataloging into interpretation or consequence
- any model-organism component directly advances a human-genetics question
- the title and abstract are accessible to readers across the field
- the cover letter can explain why AJHG is the right owner
Think Twice If
- the paper is mainly a narrow disease paper with limited general field consequence
- the methods section is the main story and the practical genetics use case is still soft in the abstract
- the model-organism work only loosely gestures toward human relevance and lacks a direct human-genetics figure or interpretation bridge
- the strongest readership is really clinical implementation, general genomics, or a more technical specialty
- the cover letter has to explain AJHG fit because the title and first figures do not
Before upload, run a human-genetics scope and readiness check to see whether the manuscript belongs in AJHG now or after another round of scientific tightening.
FAQ: What questions do authors ask before AJHG submission?
How do I submit to American Journal of Human Genetics?
Upload through Cell Press Editorial Manager at . AJHG accepts Articles (no more than 60,000 characters, up to 7 figures+tables), Reports (no more than 25,000 characters, up to 4 display items), Commentaries, and Letters. Kiran Musunuru serves as Editor-in-Chief. The journal targets first decisions within 4 weeks of submission.
How long does AJHG take to make a decision?
The published decision target is 4 weeks for first decisions. Editorial assignment runs Day 3-7; first decision arrives by Week 2-4 for papers desk-reviewed; full peer review runs Week 4-12 when sent to reviewers; revision cycle takes 4 weeks (only one revised version considered). Accepted papers publish within 2 months of acceptance.
What is the AJHG APC and submission fee?
There is no submission fee. Corresponding authors who are ASHG members do not pay page charges or color figure charges. Gold Open Access is available via the Cell Press OA route at the standard Cell Press rate; subscription-route publication carries no APC for ASHG members. Verify your institution's Cell Press Read-and-Publish coverage before upload.
What does AJHG look for in submissions?
The current ASHG journal page says AJHG welcomes Articles, Reports, and Commentaries across human genetics and genomics, including model-organism studies directly relevant to human genetics. Manuscripts should be accessible to professionals from diverse backgrounds in human genetics. In practice, editors are screening for strong human-genetics consequence, not just technically competent data generation.
What are common reasons AJHG desk-rejects manuscripts?
The three most common patterns are (1) association results without enough interpretation or follow-through, (2) model-organism work with weak direct relevance to human genetics, and (3) manuscripts whose center of gravity is clinical implementation (route to Genetics in Medicine) or general genomics (route to Genome Research). Format violations and missing sex / gender reporting per 2023 NASEM guidance are the most-easily-fixed causes of return.
Frequently asked questions
Upload through Cell Press Editorial Manager at https://www.editorialmanager.com/ajhg. AJHG accepts Articles (no more than 60,000 characters, up to 7 figures+tables), Reports (no more than 25,000 characters, up to 4 display items), Commentaries, and Letters. Kiran Musunuru serves as Editor-in-Chief. The journal targets first decisions within 4 weeks of submission.
The published decision target is 4 weeks for first decisions. Editorial assignment runs Day 3-7; first decision arrives by Week 2-4 for papers desk-reviewed; full peer review runs Week 4-12 when sent to reviewers; revision cycle takes 4 weeks (only one revised version considered). Accepted papers publish within 2 months of acceptance.
There is no submission fee. Corresponding authors who are ASHG members do not pay page charges or color figure charges. Gold Open Access is available via the Cell Press OA route at the standard Cell Press rate; subscription-route publication carries no APC for ASHG members. Verify your institution's Cell Press Read-and-Publish coverage before upload.
The current ASHG journal page says AJHG welcomes Articles, Reports, and Commentaries across human genetics and genomics, including model-organism studies directly relevant to human genetics. Manuscripts should be accessible to professionals from diverse backgrounds in human genetics. In practice, editors are screening for strong human-genetics consequence, not just technically competent data generation.
The three most common patterns are (1) association results without enough interpretation or follow-through, (2) model-organism work with weak direct relevance to human genetics, and (3) manuscripts whose center of gravity is clinical implementation (route to Genetics in Medicine) or general genomics (route to Genome Research). Format violations and missing sex/gender reporting per 2023 NASEM guidance are the most-easily-fixed causes of return.
Sources
Final step
Submitting to American Journal of Human Genetics?
Run the Free Readiness Scan to see score, top issues, and journal-fit signals before you submit.
Target journal carried over: American Journal of Human Genetics
Anthropic Privacy Partner. Zero-retention manuscript processing.
Where to go next
Same journal, next question
- How to Avoid Desk Rejection at American Journal of Human Genetics (2026)
- American Journal of Human Genetics Review Time: What Authors Can Actually Expect
- American Journal of Human Genetics 'Under Review': What Each Status Means
- American Journal of Human Genetics Impact Factor 2026: Ranking, Quartile & What It Means
Supporting reads
Conversion step
Submitting to American Journal of Human Genetics?
Anthropic Privacy Partner. Zero-retention manuscript processing.